Daiichi Sankyo (D-S) is a global pharmaceutical company with corporate origins in Japan. It provides innovative products and services in more than 20 countries around the world.
The RSA Group was asked to help Daiichi Sankyo build out their team in health economics and outcomes research (HEOR). The company wanted its HEOR team to start working on data from Phase IIa clinical trials, considerably earlier than phase III which has typically been the case so far. As HEOR is a new addition to pharmaceutical management over the last 10 years, finding individuals in this field is a challenge as there is a small pool of experience and a high demand for their expertise. The additional dimension of the earlier engagement in the development process added significantly to the complexity of RSA’s task. D-S needed an individual with a high level of technical skills and clinical development and global experience.
How our approach made a difference:
The consultants began by carrying out high level mapping of people with HEOR experience in similar therapeutic fields and in known global groups. RSA also prioritised experience of working in Japanese pharmaceutical as these individuals would understand the company culture. Using its expertise and global connections, RSA produced an initial list of 125 candidates and a shortlist was presented to the client just eight weeks post-brief. 11 candidates were interviewed and 5 made the final shortlist before an appointment was made. As a result, the new strategy director for HEOR in Europe had the right early-stage and global experience and was able to start two months later and just four months after RSA was retained.